|
Manganese superoxide dismutase -102 genotype: overall and recurrence-free survivals with radiation therapy |
||||
| Genotype |
Cases |
Deaths |
Hazard ratio minimally adjusteda (95% confidence interval) |
Hazard ratio fully adjustedb (95% confidence interval) |
|
|
||||
| Overall survival |
150 |
33 |
P for trend = 0.67 |
P for trend = 0.91 |
| CC |
93 |
20 |
1 (reference) |
1 (reference) |
| CT |
51 |
11 |
0.97 (0.46–2.04) |
0.74 (0.35–1.58) |
| TT |
6 |
2 |
1.95 (0.45–8.49) |
2.23 (0.46–10.79) |
| CC |
93 |
20 |
1 (reference) |
1 (reference) |
| CT + TT |
57 |
13 |
1.05 (0.52–2.12) |
0.82 (0.40–1.70) |
| Recurrence-free survival |
145 |
40 |
P for trend = 0.14 |
P for trend = 0.03 |
| CC |
90 |
29 |
1 (reference) |
1 (reference) |
| CT |
50 |
10 |
0.57 (0.28–1.18) |
0.40 (0.18–0.86) |
| TT |
5 |
1 |
0.60 (0.08–4.47) |
0.69 (0.09–5.46) |
| CC |
90 |
29 |
1 (reference) |
1 (reference) |
| CT + TT |
55 |
11 |
0.57 (0.28–1.16) |
0.42 (0.20–0.87) |
|
CC, homozygous for the wild-type manganese superoxide dismutase gene; CT, heterozygous for the variant genotype; TT, homozygous for the variant genotype. aMinimally adjusted model: age. bFully adjusted model: age, stage with node status at diagnosis, race, estrogen receptor status, and progesterone receptor status. | ||||
Martin et al. Breast Cancer Research 2006 8:R45 doi:10.1186/bcr1532 |
||||